York Hospital NHS Foundation Trust, Wiggington Road, York, YO31 8HE, United Kingdom.
The Mid Yorkshire Hospitals NHS Trust, Aberford Road, Wakefield, WF1 4DG, United Kingdom.
Orthop Traumatol Surg Res. 2019 May;105(3):497-501. doi: 10.1016/j.otsr.2018.12.012. Epub 2019 Mar 13.
Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening condition associated with heparin administration. Many orthopaedic units routinely prescribe low-molecular-weight heparins as thromboprophylaxis after hip and knee arthroplasty.
We postulated that routine platelet monitoring following heparin administration is of no clinical benefit. We therefore asked: firstly, what was the rate of thrombocytopenia in a large population of patients undergoing lower limb arthroplasty? Secondly, did this rate justify routine platelet monitoring?
Unless contraindicated, all patients (n=1999, 53.05% female, mean age 69.23 years) at a UK district general hospital undergoing hip and knee arthroplasty were given daily prophylactic enoxaparin. Platelet counts were obtained between the 8th and 10th postoperative days and compared to preoperative baseline. A > 50% fall in platelet count was classified as "possible HIT". The minimal acceptable risk of thrombocytopenia was defined using The American College of Chest Physicians (ACCP) 2012 guidelines, which recommend monitoring platelet counts in patients receiving heparin where the expected risk of HIT is>1% and by descriptive cost-benefit analysis based on the cost of routine platelet monitoring in the clinical setting.
Complete results were available for 1361 (68.1%) patients, comprising: 653 primary hips, 22 revision hips, 1 hip resurfacing, 665 primary knees, 19 revision knees and 1 unicompartmental knee replacement. Mean platelet level was 281.9×109/L preoperatively and 527.83×109/L postoperatively. Forty-four patients (3.2%) experienced a postoperative fall in platelet levels. However, no patient experienced a drop in platelets to less than 50% of the preoperative value.
The incidence of HIT in the elective arthroplasty population is low. Therefore, routine postoperative monitoring of platelets is not necessary in this population of patients.
II, prospective study.
肝素诱导的血小板减少症(HIT)是一种与肝素给药相关的潜在危及生命的病症。许多矫形外科单位通常在髋关节和膝关节置换术后开低分子量肝素作为血栓预防。
我们假设肝素给药后常规血小板监测没有临床益处。因此,我们提出以下问题:首先,在进行下肢关节置换术的大量患者中,血小板减少症的发生率是多少?其次,这个发生率是否证明常规血小板监测是合理的?
除非有禁忌症,英国一家地区综合医院的所有(n=1999,53.05%为女性,平均年龄 69.23 岁)接受髋关节和膝关节置换术的患者均给予每日预防性依诺肝素。在术后第 8 至 10 天之间获得血小板计数,并与术前基线进行比较。血小板计数下降>50%被归类为“可能的 HIT”。血小板减少症的最小可接受风险使用美国胸科医师学会(ACCP)2012 指南来定义,该指南建议在肝素治疗中监测血小板计数,其中预期的 HIT 风险>1%,并基于常规血小板监测在临床环境中的成本效益分析进行描述性。
1361 名(68.1%)患者的完整结果可用,其中包括:653 例初次髋关节置换术、22 例髋关节翻修术、1 例髋关节表面置换术、665 例初次膝关节置换术、19 例膝关节翻修术和 1 例单髁膝关节置换术。术前平均血小板水平为 281.9×109/L,术后为 527.83×109/L。44 名患者(3.2%)术后出现血小板水平下降。然而,没有患者的血小板下降到术前值的 50%以下。
择期关节置换术患者的 HIT 发生率较低。因此,在该患者人群中,术后常规监测血小板是没有必要的。
II 级,前瞻性研究。